Table 1.
Clinical features, prior treatments and responses from pembrolizumab for 19 patients with RR-NKTCL.
| Patient ID | Sex | Age at diagnosis | Ann arbor staging | ECOG | IPI | OS (months) | Status as January 2020 | PD-L1 positivity | Treatments prior to Pembrolizumab | Pembrolizumab treatment | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTx (cycles) | RT | TP | Best Responsea (Lugano 2014) | DORb, months | |||||||||
| Responders (n = 9) | |||||||||||||
| NKTL1 | M | 49 | IV | 1 | 2 | 73 | Alive | 100% |
GELOX (4), SMILE (5), Romidepsin+Bortezomib (1), BV+Benda (1), Lenalidomide+Dara (1) |
Nil | Nil | CR: PET/CT | 45 |
| NKTL26 | M | 32 | I | 1 | 1 | 68 | Alive | 40% |
SMILE (2), Vinc+DXM+Lasp (1), GELOX (6) |
Yes | Nil | CR: PET/CT | 49 |
| NKTL28 | M | 46 | IV | 3 | 4 | 33 | Alive | 70% |
SMILE (2), P-GEMOX (1) |
Nil | Nil | CR: PET/CT | 31 |
| NKTL29 | M | 48 | I | 0 | 0 | 37 | Alive | 6% | Ifos+MTX+VP+DXM+Pasp (4) | Nil | Nil | CR: PET/CT | 34 |
| NKTL30 | M | 38 | IV | 3 | 4 | 43 | Alive | 60% | SMILE (5) | Nil | Nil | CR: PET/CT | 36 |
| NKTL31 | M | 27 | IV | 0 | 5 | 91 | Alive | 20% |
Lasp+DXM+Vinc+AraC (4), CHOP (2), P-GEMOX (2), DXM+Pasp+mitoxantrone+VP (4) P-GEMOX+VP (2) |
Nil | Auto-HSCT with BEAM + Thalidomide | CR: CT & MRI | 41 |
| NKTL43 | M | 29 | IV | 2 | 3 | 116 | Dead | 90% |
m-BACOD (4), SIMPLE (5), SMILE (3) |
Yes | Nil |
CR: PET/CT Patient subsequently underwent MUD BMT and died from GVHD. |
14 |
| NKTL44 | M | 66 | IV | 1 | 2 | 37 | Dead | 90% | SIMPLE (6) | Nil | Nil | PR: DOD | 3 |
| NKTL45 | M | 42 | IV | 1 | 3 | 94 | Dead | 65% |
SMILE (6), GEMOX (1) |
Nil | Allo-HSCT | PR: DOD | 2 |
| Non-responders (n = 10) | |||||||||||||
| NKTL25 | M | 30 | IV | 0 | 2 | 14 | Dead | 72% |
SMILE (6), GEMOX (1) |
Yes | Allo-HSCT | PD: DOD | NA |
| NKTL27 | M | 59 | IV | 0 | 2 | 19 | Dead | 50% |
SMILE (3), GIFOX (4) |
Nil | Nil | PD: DOD | NA |
| NKTL46 | F | 62 | IV | 3 | 5 | 12 | Dead | 12% | CHOP (1), P-GEMOX (1), Thalidomide+Prednisone (1), Lenalidomide+Prednisone (1), Abraxane (1) | Nil | Nil | PD: DOD | NA |
| NKTL47 | M | 51 | IV | 1 | 3 | 5 | Dead | 95% |
SMILE (1), MILE (2), GIFOX (4) |
Nil | Nil | PD: DOD | NA |
| NKTL128 | F | 62 | IV | - | - | 31 | Dead | 21% |
GEMOX (6), Chidamide(1) |
Nil | Nil | SD: DOD | NA |
| NKTL248 | F | 79 | IV | 1 | 3 | 10 | Dead | 100% |
VIDL (1), GDP (2), Avelumab (2) |
Nil | Nil | PD: DOD | NA |
| NKTL249 | M | 45 | IV | 1 | 2 | 4 | Dead | 100% |
VIDL (2), GDP (1), |
Nil | Nil | PD: DOD | NA |
| NKTL250 | M | 45 | IV | 1 | 2 | 12 | Dead | 100% | VIDL (4) | Nil | Auto-HSCT | PD: DOD | NA |
| NKTL251 | M | 66 | I | 1 | 1 | 28 | Dead | 100% |
Cisplatin (6), Dara (10), GDP (4), Avelumab (3) |
Yes | Nil | PD: DOD | NA |
| NKTL252 | M | 73 | IV | 2 | 3 | 2 | Dead | 0% | Lasp (2) | Nil | Nil | PD: DOD | NA |
aAs assessed by Lugano 2014 criteria: CR Complete response, PR partial response, SD stable disease, PD progressive disease. MUD BMT, matched unrelated donor bone marrow transplant; GVHD, graft versus host disease; DOD, died of disease.
bDOR: Durability of response was recorded in months from documentation of response until PD as of January 2020.
Abbreviations for treatment regimens: BV brentuximab vedotin, Benda bendamustine, Dara daratumumab, Vinc vincristine, DXM dexamethasone, Lasp L-asparaginase, Ifos ifosfamide, MTX methotrexate, VP etoposide, Pasp Pegaspargase, AraC cytarabine, ND not done, VIDL etoposide, ifosfamide, dexamethasone, and L-asparaginase, GDP gemcitabine, dexamethasone, cisplatin, P-GEMOX Pegaspargase, gemcitabine, and oxaliplatin, SMILE, Dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide; CHOP cyclophosphamide, doxorubicin, vincristine, prednisone, GIFOX Gemcitabine, ifosfamide, oxaliplatin and rituximab, SIMPLE, Cisplatin, Gemcitabine, Ifosfamide, Etoposide, L-asparaginase and Dexamethasone.
ECOG eastern cooperative oncology group, IPI international prognostic index, OS overall survival, RT radiotherapy, TP transplant.